Atypical antipsychotic drugs, dementia, and risk of death [2]

JAMA

Volumn 295, Issue 5, 2006, Pages 495-496

  Gill, Sudeep S ^a   Seitz, Dallas ^b   Rochon, Paula A ^c  

^a Department of Medicine ^*

^b QUEEN S UNIVERSITY   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

CLINICAL TRIAL; DELIRIUM; DEMENTIA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; LETTER; MENTAL DISEASE; META ANALYSIS; PRIORITY JOURNAL; SYSTEMATIC REVIEW; TOXICITY; MORTALITY; NOTE; RISK;

ANTIPSYCHOTIC AGENTS; DELIRIUM; DEMENTIA; HUMANS; MORTALITY; RISK;

EID: 32044437789     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.295.5.495-b     Document Type: Letter

References (5)

1. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-1943.
2. Leslie DL, Zhang Y, Holford TR, Bogardus ST, Leo-Summers LS, Inouye SK. Premature death associated with delirium at 1-year follow-up. Arch Intern Med. 2005;165:1657-1662.
3. American Psychiatric Association. Practice guideline for the treatment of patients with delirium. Am J Psychiatry. 1999;156(5 suppl):1-20.
4. Cole MG, Primeau FJ, Elie M. Delirium: prevention, treatment, and outcome studies. J Geriatr Psychiatry Neurol. 1998;11:126-137.
5. Inouye SK, Bogardus ST, Charpentier PA, et al. A multicomponent intervention to prevent delirium in hospitalized older patients. N Engl J Med. 1999;340:669-676.